Twenty years of MOPP therapy for Hodgkin's disease.

@article{Longo1986TwentyYO,
  title={Twenty years of MOPP therapy for Hodgkin's disease.},
  author={D. Longo and Robert C. Young and Margaret N. Wesley and Susan Molloy Hubbard and Patricia L. Duffey and Elaine S. Jaffe and Vincent T. Devita},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1986},
  volume={4 9},
  pages={
          1295-306
        }
}
  • D. LongoR. Young V. Devita
  • Published 1 September 1986
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
The results of treatment of 198 patients with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) for Hodgkin's disease were analyzed after a median of 14 years of follow-up. Throughout the period of follow-up, 103 patients have remained continuously free of disease. Review of biopsy specimens of 43 patients originally classified as Hodgkin's disease, lymphocyte-depleted type, revealed that ten of these patients actually had diffuse immunoblastic or large cell non-Hodgkin's… 

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.

This study adds further support to the view that chlorambucil is as effective and less toxic than mustine in combination chemotherapy for HD and suggests that MOPP chemotherapy is no longer routinely indicated for HD.

Ten-year nodular sclerosis Hodgkin's disease and second malignancies.

Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.

  • D. LongoA. Russo V. Devita
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1991
The retrospective analysis shows a nearly significant difference in disease-free survival favoring combined modality treatment and overall survival differences between patients treated with MOPP alone and those treated with combinedModality therapy were not significantly different because of the mortality related to late complications of combinedmodality treatment.

Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in hodgkin's disease. An analysis of long‐term follow‐up

Patients treated with nitrogen mustard, vincristine, procarbazine, and prednisolone chemotherapy for Hodgkin's disease have been observed for a median of 10.2 years and patients who achieved a CR to MOPP had a significantly improved survival.

Conventional salvage therapy for Hodgkin's lymphoma.

About one-third of all patients with Hodgkin’s disease will eventually need salvage therapy, and patients in advanced stages with certain risk factors, such as very extensive disease, B-symptoms, an excessively high erythrocyte sedimentation rate, or elevated alkaline phosphatase, have a cure rate of less than half when followed-up long enough.

Efficacy of ABVD Therapy in Resistant Hodgkin's Disease.

The efficacy of ABVD combination chemotherapy in resistant or relapsed HD is confirmed and clinical or laboratory data present before therapy with ABVD were associated with a higher index of response or longer survival.

Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years.

The overall median survival from presentation is 14 years, being the same for patients in CR and PR with minimal residual abnormality (good partial remission, GPR), and being better for those for whom remission was achieved than those for which it was not.

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant.

It is suggested that long-term vinblastine therapy may be potentially curative and should be considered as initial therapy for such patients with Hodgkin's disease who relapsed after autologous BMT.

Chemotherapy With cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for hodgkin disease: Fourteen‐year follow‐up results

It is confirmed that cure is possible with alternative regimens to MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone), and at the current time, 12 of the 28 patients are continuously disease‐free 12.8 to 15.3 years after completing induction chemotherapy.

CCNU , VINBLASTINE , PROCARBAZINE AND PREDNISONE

Results confirmed the mild neurological and gastroenteric side effects of CVPP that make it an interesting MOPP-variant regimen that is most indicated when a regimen devoid of cardiac and pulmonary toxicity is required for association with full-dosage mediastinal radiotherapy, as is often the case in early, unfavorable Hodgkin’s disease.
...

References

SHOWING 1-10 OF 31 REFERENCES

MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients

A decreased duration of remission correlated with older age, the presence of systemic symptoms, and bone marrow involvement, as well as prior radiotherapy and prior chemotherapy.

Alternating drug combinations in the treatment of advanced Hodgkin's disease.

It is concluded than alternating non-cross-resistant combinations appear promising in the management of advanced Hodgkin's disease and are worthy of trial in other malignant diseases.

Prognostic factors for stage IV Hodgkin's disease treated with MOPP, with or without bleomycin

Patients with Stage IV Hodgkin's disease treated with MOPP alone should receive the highest tolerable dose of nitrogen mustard early in their treatment, since those receiving lower doses have a higher risk of relapse.

Reasons for failure of MOPP to cure Hodgkin's disease The importance of dose and schedule

It appears that new treatment approaches are needed for patients with B symptoms, and that failure to deliver MOPP on schedule in the planned dose increases the risk of relapse.

Prednisone in MOPP chemotherapy for Hodgkin's disease.

High remission rates have been produced by MOPP chemotherapy in patients with advanced Hodgkin's disease, but the prednisone component has caused adverse effects in patients who have undergone radiotherapy, but it is difficult to know what accounted for the substantial differences in the findings.

The treatment of stage IIIA Hodgkin's disease.

Although overall survival of patients receiving TNI was identical to that of those receiving MVPP, TNI must be considered inappropriate therapy for stage IIIA Hodgkin's disease if permanent freedom-from-recurrence is the goal.

Treatment of Hodgkin's disease using intensive chemotherapy followed by irradiation.

Hematologic neoplasia in patients treated for Hodgkin's disease.

We studied 680 patients with Hodgkin's disease, treated at Stanford University Medical Center from July 1, 1968, through December 31, 1975, to determine the risk of development of hematologic

A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (mopp) vs. nitrogen mustard in advanced hodgkin's disease

A randomized study of patients with advanced Hodgkin's disease was designed to determine whether the improved therapeutic effectiveness of combination chemotherapy was due to the use of a combination